期刊文献+

IHC和FISH联合检测278例浸润性乳腺癌中HER-2状态的研究 被引量:5

Investigation of HER-2 status evaluated by both IHC and FISH approaches in 278 cases of invasive breast carcinoma
暂未订购
导出
摘要 目的:同时应用免疫组织化学(IHC)和荧光原位杂交(FISH)技术,检测278例浸润性乳腺癌组织中的人类表皮生长因子受体2(Human Epidermal Growth Factor Receptor2,HER-2),以探讨两种方法检测HER-2状态的符合率。方法:用IHC和FISH法分别检测278例浸润性乳腺癌组织中HER-2蛋白的表达和HER-2基因状态,以比较两种方法的阳性率和准确率。结果:IHC和FISH检测HER-2的总符合率为83.9%,Kappa系数为0.650(P<0.001)。130例IHC标记HER-2结果显示为++的病例中,44例(33.8%)Fish为阳性,54例结果1HC为阳性或+的病例中的5例(9.3%),经FISH检测证实HER-2基因有扩增。而94例IHC结果显示为+++的病例中,有3例(20.2%)FISH结果为阴性。在130例IHC显示++的病例中,3例FISH结果为模棱两可。结论:IHC和FISH检测HER-2的符合率为83.9%,对IHC标记HER-2结果为++的病例,用FISH检测大多能得到满意结果。对极少数HER-2基因扩增为临界状态的乳腺癌病例需结合其他检查结果综合考虑。 Objective Breast cancer is the most common malignancy in the women.If the patients with HER-2 positive have invasive breast carcinoma,they can obtain beneficial results from the targeting therapy by Herceptin.Therefore,accurate detection the HER-2 gene status is the key point to select the candidates for Herceptin treatment.At present,the IHC and FISH techniques are the most popular methods used to evaluate the HER-2 status.Even though there is high concordance rate between the 2 methods,the discrepancies in positive rate of HER-2 between these two different approaches exist obviously.This research serves to investigate the concordance rate between the two different methods to test the HER-2 status,respectively.Methods Both IHC and FISH techniques were performed separately in 278 cases to detect the status of HER-2 protein expression and gene amplification.Statistically,SPSS11.5 software was applied to analyse the results obtained in both methods.Results The total concordance rate of HER-2 between IHC and FISH trials was 83.9%,with Kappa of 0.650(P0.001).Forty-four among 130 cases(33.8%) with ++ IHC and 5/54(9.3%) with 0 or + IHC cases were positive in FISH.Three among the 94(20.2%) with +++ IHC cases were negative in FISH,and 3 of the 130 cases with ++ IHC were equivocal in FISH.Conclusions The concordance rate in our investigation between IHC and FISH of HER-2 was 83.9%,and FISH could get satisfying result in most of the ++ IHC cases.However,comprehensive consideration should be taken together with other testing results in those few equivocal cases.
出处 《外科理论与实践》 2010年第5期499-503,共5页 Journal of Surgery Concepts & Practice
基金 2009上海市高校人才专项基金
关键词 浸润性乳腺癌 人类表皮生长因子受体2 免疫组化 荧光原位杂交 Invasive breast carcinoma HER-2 IHC FISH
  • 相关文献

参考文献20

  • 1Chu D,Lu J.Novel therapies in breast cancer:what is new from ASCO 2008[J].J Hematol Oncol,2008,1:16.
  • 2Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 3郑莹,李德録,向泳梅,李新建.上海市区乳腺癌流行现状及趋势分析[J].外科理论与实践,2001,6(4):219-221. 被引量:90
  • 4Kurosumi M.Recent trends of HER-2 testing and trastuzumab therapy for breast cancer[J].Breast Cancer,2009,16(4):284-287.
  • 5Dizdar O,Altundag K.Emerging drugs in metastatic breast cancer[J].Expert Opin Emerg Drugs,2009,14(1):85-98.
  • 6Hyams DM.Understanding tumor profiling and assessing treatment[J].Manag Care,2008,17(7 Suppl 7):4-8.
  • 7Paterson MC,Dietrich KD,Danyluk J,et al.Correlation between c-erbB-2 amplification and risk of recurrent disense in node-negative breast cancer[J].Cancer Res,1991,51(2):556-567.
  • 8Seshadri R,Firgaira FA,Horsfall DJ,et al.Clinical significance of HER-2/neu oncogene amplification in primary breast cancer.The South Australian Breast Cancer Study Group[J].J Clin Oncol,1993,11(10):1936-1942.
  • 9Geyer FC,Marchio C,Reis-Filho JS.The role of molecular analysis in breast cancer[J].Pathology,2009,41(1):77-88.
  • 10Tanner M,Gancberg D,Di Leo A,et al.Chromogenic in situ hybridization:a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples[J].Am J Pathol,2000,157(5):1467-1472.

二级参考文献2

共引文献89

同被引文献58

  • 1裴静,余昌俊,王本忠,胡向阳.ER、PR、HER-2在绝经后乳腺浸润性导管癌组织中的表达及临床病理相关性的研究[J].安徽医科大学学报,2005,40(1):41-43. 被引量:12
  • 2罗建湘,刘载道,冯雪萍,等.荧光原位杂交与免疫组织化学对乳腺癌HER-2基因检测的研究[C].//2011年全国西安病理技术学术会议暨全军第七届病理技术学术会议论文集,2011:98-101.
  • 3Gokhale S, Gatalica Z, Mohammad A, et al. FISH for HER- 2/neu in breast cancer: Standardization makes the differencet[J]. Indian J Cancer,2004,41(4) : 152-158.
  • 4Ray A,Sharma BK, Kaur S, et al. Overepression of c-erbB-2 oncoprotein and associated pathobiological factors in invasive primary breast cancer[J]. Indian J Exp Biol, 2004, 42 (3) : 253-258.
  • 5罗建湘;刘载道;冯雪萍.荧光原位杂交与免疫组织化学对乳腺癌HER-2基因检测的研究[A],201198-101.
  • 6Ray A,Sharma B K,Kaur S. Overepression of c-erbB-2 on-coprotein and associated pathobiological factors in invasive primary breast cancer[J].{H}Indian Journal of Experimental Biology,2004,(3):253-258.
  • 7Chu D,Lu J. Novel therapies in breast cancer:what is new from ASCO 2008[J].J Hematol Oncol,2008.16.
  • 8Greenlee RT,Hill-Harmon MB,Murray T. Cancer statistics[J].CA Cancer J C1in,2001,(01):15-36.
  • 9Kurosumi M. Recent trends of Her-2 testing and trastuzumab therapy for breast cancer[J].Breast Cancer,2009,(04):284-287.
  • 10Dizdar O,Altundag K. Emerging drugs in metastatic breast cancer[J].Expert Opinion on Emerging Drugs,2009,(01):85-98.

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部